Showing 7691-7700 of 10621 results for "".
- AI-Driven Tool Flags High Heart Failure Risk in Diabetic Patientshttps://reachmd.com/news/ai-driven-tool-flags-high-heart-failure-risk-in-diabetic-patients/2468515/Researchers at UT Southwestern Medical Center have unveiled a machine learning model designed to identify diabetic patients at elevated risk for heart failure due to a distinct heart condition known as diabetic cardiomyopathy. Published in the European Journal of Heart Failure, this tool
- Sleep Apnea Contributes to Dementia in Older Adults, Especially Womenhttps://reachmd.com/news/sleep-apnea-contributes-to-dementia-in-older-adults-especially-women/2468522/A common yet underdiagnosed sleep disorder contributes to the development of dementia among adults — particularly women, a Michigan Medicine study suggests. Investigators uncovered this by examining survey and cognitive screening data from more than 18,500 adul
- Search Continues for a Treatment that Reduces Long COVID Symptomshttps://reachmd.com/news/search-continues-for-a-treatment-that-reduces-long-covid-symptoms/2468517/The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. The
- The Complex Impact of Menopausal Hormone Therapy on Brain Healthhttps://reachmd.com/news/the-complex-impact-of-menopausal-hormone-therapy-on-brain-health/2468481/New research underscores the nuanced effects of menopausal hormone therapy (MHT) on brain health, revealing how individual factors such as age, duration of therapy, and surgical history influence outcomes. Published in eLife, this study delves into the intricate relationships between MHT
- Ozempic and Hair Loss: Exploring the Link and Managing Side Effectshttps://reachmd.com/news/ozempic-and-hair-loss-exploring-the-link-and-managing-side-effects/2468501/Hair loss is emerging as a surprising and concerning side effect among some Ozempic users, sparking questions about the causes and potential solutions. Ozempic, known generically as semaglutide, was originally developed for type 2 diabetes but is increasingly u
- New Exendin-PET Scan Significantly Improves Detection of Insulinomashttps://reachmd.com/news/new-exendin-pet-scan-significantly-improves-detection-of-insulinomas/2468479/A new PET scan, the Exendin-PET, is showing remarkable accuracy in identifying benign insulin-producing tumors, or insulinomas, in the pancreas. This research, led by Radboud University Medical Center, addresses a significant gap in current scanning techniques, which often miss these tumors. Insu
- Obesity and Diabetes Significantly Increase Risk of Liver Cancer Recurrence, Study Showshttps://reachmd.com/news/obesity-and-diabetes-significantly-increase-risk-of-liver-cancer-recurrence-study-shows/2468472/A new study from Osaka Metropolitan University reveals that obesity and diabetes can significantly increase the risk of hepatocellular carcinoma (HCC) relapse after liver resection, underlining the need for managing these conditions in cancer survivors. Hepatocellular carcino
- NCH Health: New Guidelines Recommend Lowering the Age for Colorectal Cancer Screeninghttps://reachmd.com/news/nch-health-new-guidelines-recommend-lowering-the-age-for-colorectal-cancer-screening/2468466/Colorectal cancer (CRC) is the third-leading cause of cancer-related deaths among men and the fourth among women in the United States. When considered together, CRC is the second leading cause of cancer deaths nationwide. In 2021, the United States Preventative Services Task Fo
- COVID-19 Linked to Increased Risk of Acute Kidney Disorders, Reveals New Studyhttps://reachmd.com/news/covid-19-linked-to-increased-risk-of-acute-kidney-disorders-reveals-new-study/2468451/Researchers from West China Hospital, Sichuan University, have conducted a study revealing a significant association between COVID-19 and acute kidney disorders (AKD), including acute kidney injury (AKI), that varies over time. The study, led by Dr. Li Chunyang and Dr. Zeng Xiaoxi from
- New Therapy Combines Procedure with Semaglutide to Potentially End Insulin Use in Type 2 Diabeteshttps://reachmd.com/news/new-therapy-combines-procedure-with-semaglutide-to-potentially-end-insulin-use-in-type-2-diabetes/2468420/A groundbreaking study presented at UEG Week 2024 has revealed a promising new treatment that could transform the management of type 2 diabetes (T2D). This innovative approach, combining the Re-Cellularization via Electroporation Therapy (ReCET) procedure with semaglutide, led to 86% of participa